Similar to This
Previous
Profile picture of swp.de
swp.de
Credibility C+
 Oct 15
Multi-million euro offer for plant in Tübingen: 500 CureVac employees to be taken on
swp.de/lokales/tuebingen/millionenangebot-fuer-werk-in-tuebingen-500-mitarbeiter-von-curevac-sollten-uebernommen-werden-79573804.html
Multi-million euro offer for plant in Tübingen: 500 CureVac employees to ...
1 similar article
0
0
Profile picture of deraktionaer.de
deraktionaer.de
C
 Oct 14
Black day for BioNTech - | this is important now: BioNTech's stock fell by over 7% after a study setback with BNT113. The Phase 3 trial showed no better ...
deraktionaer.de/artikel/pharma-biotech/schwarzer-tag-fuer-biontech-das-ist-jetzt-wichtig-20416593.html
Black day for BioNTech - | this is important now
0 similar articles
0
0
Profile picture of deraktionaer.de
deraktionaer.de
C
 Oct 15
BioNTech stock: Surprising cancellation - | new details: BioNTech closes its Tübingen mRNA plant despite a multi-million euro offer. Why the talks ultimately ...
deraktionaer.de/artikel/deraktionaerplus/biontech-aktie-ueberraschende-absage-neue-details--20417497.html
BioNTech stock: Surprising cancellation - | new details
0 similar articles
0
0
Profile picture of Allgemeine Zeitung
Allgemeine Zeitung
C+
 Oct 13
Why BioNTech continues clinical trial of cancer drug despite setback: BioNTech's drug BNT113 initially shows no effect on the progression of the disease ...
allgemeine-zeitung.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/warum-biontech-krebsstudie-trotz-rueckschlag-fortsetzt-6542280
Why BioNTech continues clinical trial of cancer drug despite setback
4 similar articles
0
6
Profile picture of Oberhessische Presse
Oberhessische Presse
C
 Oct 09
Marburg: After BioNTech closure - | Mayor Thomas Spies writes open letter to Chancellor Merz
op-marburg.de/wirtschaft/regional/marburg-nach-biontech-schliessung-oberbuergermeister-thomas-spies-schreibt-offenen-brief-an-kanzler-EG6OWFZEERFLRPPV6S5U47B6PU.html
Marburg: After BioNTech closure - | Mayor Thomas Spies writes open letter ...
1 similar article
0
22
Profile picture of stuttgarter-nachrichten.de
stuttgarter-nachrichten.de Oct 06
OpinionMillion-dollar bonuses: Boris Palmer rants: Payments to CureVac manager "outrageous"
stuttgarter-nachrichten.de/wirtschaft/millionen-boni-boris-palmer-empoerend-hohe-zahlungen-an-curevac-manager-79539819.html
Million-dollar bonuses: Boris Palmer rants: Payments to CureVac manager ...
1 similar article
0
4
Profile picture of Manager Magazin
Manager Magazin
C
 Oct 05
The restart of the BioNTech founders: This is what the financial restart of the BioNTech founders could look like
manager-magazin.de/unternehmen/industrie/biontech-gruender-wie-ugur-sahin-und-oezlem-tuereci-ihr-neues-start-up-finanzieren-wollen-a-05208c93-2d49-4985-8154-cd6808d801de
The restart of the BioNTech founders: This is what the financial restart ...
0 similar articles
0
0
Profile picture of deraktionaer.de
deraktionaer.de
C
 Sep 23
Moderna stock knows no bounds - | what's going on with BioNTech?: The stock has roughly tripled since the positive data was released.
deraktionaer.de/artikel/pharma-biotech/moderna-aktie-kennt-kein-halten-mehr-was-ist-mit-biontech-los-20409301.html
Moderna stock knows no bounds - | what's going on with BioNTech?
0 similar articles
0
0
Profile picture of deraktionaer.de
deraktionaer.de
C
 Sep 16
BioNTech: Triple buy recommendation - | is it starting now?: BioNTech receives positive analyst opinions after promising studies on Gotistobart and a combination ...
deraktionaer.de/artikel/pharma-biotech/biontech-dreifache-kaufempfehlung-gehts-jetzt-los-20408884.html
BioNTech: Triple buy recommendation - | is it starting now?
9 similar articles
0
0
Profile picture of deraktionaer.de
deraktionaer.de
C
 Aug 21
After Moderna's success: Attention turns to BioNTech - | this is what's planned now
deraktionaer.de/artikel/pharma-biotech/nach-moderna-erfolg-blick-richtet-sich-auf-biontech-das-ist-jetzt-geplant-20407208.html
After Moderna's success: Attention turns to BioNTech - | this is ...
5 similar articles
1
0
Profile picture of deraktionaer.de
deraktionaer.de
C
 Jun 04
BioNTech and Eli Lilly warn: Billions in investments at risk: BioNTech and Eli Lilly are sounding the alarm over the potential consequences of pharmaceutical ...
deraktionaer.de/artikel/pharma-biotech/biontech-und-eli-lilly-warnen-milliarden-investitionen-gefaehrdet-20402237.html
BioNTech and Eli Lilly warn: Billions in investments at risk
0 similar articles
0
0
Profile picture of deraktionaer.de
deraktionaer.de
C
 Jun 01
BioNTech with new data - | but is it enough?: BioNTech and Bristol Myers Squibb present promising results on pumitamig, an immunomodulator against advanced lung ...
deraktionaer.de/artikel/pharma-biotech/biontech-mit-neuen-daten-doch-reicht-das-20401923.html
BioNTech with new data - | but is it enough?
0 similar articles
0
0
Profile picture of deraktionaer.de
deraktionaer.de
C
 Feb 20
BioNTech sues Moderna - | the details: BioNTech sues Moderna for patent infringement; shares of both companies remain stable.
deraktionaer.de/artikel/pharma-biotech/biontech-verklagt-moderna-die-details-20395822.html
BioNTech sues Moderna - | the details
1 similar article
0
2
Profile picture of Manager Magazin
Manager Magazin
C
 Jan 23
Extra investment: Why pharmaceuticals could be the hottest stock bet of 2026: AI dominates the stock market, but the big rally is in danger of running out of ...
manager-magazin.de/finanzen/geldanlage/pharmaaktien-die-vielleicht-heisseste-aktienwette-2026-a-77e68f2a-fb5b-4732-9553-90aef58de6ab
Extra investment: Why pharmaceuticals could be the hottest stock bet of ...
0 similar articles
1
0
Profile picture of BÖRSE ONLINE
BÖRSE ONLINE
C
 Dec 15 25
BioNTech stock: Hope is back: BioNTech acquires CureVac and strengthens market position; blockbuster potential for new cancer drug BNT327.
boerse-online.de/nachrichten/aktien/biontech-aktie-die-hoffnung-ist-zurueck-20392023.html
BioNTech stock: Hope is back
0 similar articles
0
1
Profile picture of finanzen.net
finanzen.net
C
 Dec 08 25
NASDAQ-listed BioNTech stock poised for gains: Study raises hopes for a milestone in lung cancer treatment
finanzen.net/nachricht/aktien/ueberlebensvorteil-rueckenwind-fuer-biontech-aktie-neue-studiendaten-machen-hoffnung-fuer-lungenkrebsmittel-00-15341631
NASDAQ-listed BioNTech stock poised for gains: Study raises hopes for a ...
1 similar article
0
0
Profile picture of Handelsblatt
Handelsblatt
B+
 Aug 04 25
Pharma industry: Biontech halves loss - cancer strategy picks up speed: Biontech more than doubled its turnover in the second quarter. The company plans to spend ...
handelsblatt.com/unternehmen/industrie/pharmaindustrie-biontech-halbiert-verlust-krebsstrategie-nimmt-fahrt-auf/100146054.html
Pharma industry: Biontech halves loss - cancer strategy picks up speed
Key FactsBiontech Boosts Growth with Cancer Strategy and Deals
Aug 4, 2025 · Reading time: ~45 sec.
Summary created with AI assistance · Source: handelsblatt.com
  • Biontech doubled its revenue to €260.8 million in Q2 and reduced its net loss to €386.6 million.

  • The company is refocusing on oncology, strengthened by a partnership with Bristol Myers Squibb and the planned acquisition of Curevac.

  • Over 20 studies involving BNT327 across various tumors are underway, with a pivotal breast cancer phase-3 study starting this year.

  • Revenue is forecasted to decline in 2025 while R&D spending is expected to increase to as much as €2.8 billion.
    • We continue to invest significantly in the implementation of our strategy, and our operational and financial measures are showing initial tangible results.
    — CFO Ramón Zapata discusses Biontech's progress in cancer research.
7 similar articles
17
127
Profile picture of deraktionaer.de
deraktionaer.de
C
 May 27 25
"The next era of cancer medicine": BioNTech data ahead: BioNTech presents cancer medicine data at the ASCO Annual Meeting.
deraktionaer.de/artikel/pharma-biotech/die-naechste-aera-der-krebsmedizin-biontech-daten-voraus-20380892.html
Key FactsBioNTech Advances New Cancer Treatment Data
May 27, 2025 · Reading time: ~45 sec.
Summary created with AI assistance · Source: deraktionaer.de
  • BioNTech will present several significant cancer medicine data sets at the ASCO meeting in Chicago.

  • The spotlight is on the antibody candidate BNT327, designed to enhance anti-tumor effects via dual mechanisms.

  • Additional study results for BNT324/DB-1311 in prostate cancer and other candidates will also be shared.

  • BioNTech envisions the future of oncology as driven by combining innovative therapies yielding synergistic benefits.
    • We believe that the next era of cancer medicine will be characterized by the interplay of complementary mechanisms of action and innovative therapeutic modalities, whose full potential can be unleashed through synergistic effects.
    — Özlem Türeci, co-founder and CMO of BioNTech, ahead of the ASCO annual meeting.
0
6
0
1
Next